WASHINGTON (AP) -- Biopharmaceutical company Emergent BioSolutions Inc. spent $560,000 lobbying the federal government in the second quarter, according to a recent disclosure form.The Rockville, Md.-based company lobbied on appropriations and the government stockpiling of biodefense vaccines. Emergent BioSolutions holds a three-year, $448 million contract with the Department of Health and Human Services for the anthrax vaccine BioThrax.
Besides Congress, Emergent lobbied the departments of Defense and Health and Human Services in the April-June period, according to the form posted online July 14 by the House clerk's office.
Read More